Patient stories

View different patients' experiences living with type 1 Gaucher disease and taking Zavesca therapy.

Learn more

Zavesca Cares™

Introducing Zavesca Cares. Learn more about the program and how to enroll.

Learn more

National Gaucher Foundation

This organization is dedicated to promoting education, awareness, and treatment of Gaucher disease.

Learn more

Understanding Your Zavesca Therapy is an Important First Step.
Click to download

Simple Steps for making the most of Zavesca.
Click to download

Help yourself by making healthy choices.
Click to download

Introducing Zavesca Cares. Learn more about the program and how to enroll.
Click to download

Learn More About People Who Take Zavesca

Zavesca may provide benefits to people with type 1 Gaucher disease. Still, keep in mind that Zavesca can take some time to work in ways you will notice. Even though some people taking Zavesca may not feel better right away; they can experience benefits that their doctors can measure.

You can learn more by watching stories about people living with type 1 Gaucher disease and taking Zavesca therapy.

Zavesca Patient Support

Zavesca Patient Support is provided by Actelion Pharmaceuticals US, Inc., the company that makes Zavesca and by CuraScript, Inc., a specialty pharmacy that sends that sends Zavesca directly to patients.

  • Zavesca Cares is a one-on-one support program for people taking Zavesca and is provided by Actelion Pharmaceuticals US, Inc.
  • Zavesca is distributed by CuraScript, Inc., a specialty pharmacy that ensures that patients have continued access to their medication and provides Zavesca at no cost to eligible patients.

Zavesca Cares

Zavesca Cares offers supplemental counseling and educational support services related to your Zavesca therapy, all at no cost to you. Learn more about Zavesca Cares or download the enrollment form (for patients who have already been prescribed Zavesca by their doctor).

You are eligible for Zavesca Cares if:

  • You've been diagnosed with type 1 Gaucher disease
  • You are taking Zavesca, and
  • You are 18 years or older

CuraScript patient support

CuraScript's Zavesca team is made up of registered nurses and pharmacists who are available to answer your questions about Zavesca, including:

For more information about Zavesca, Zavesca Financial Support, or CuraScript, call CuraScript's Zavesca Team Monday through Friday, 8 am to 6 pm Eastern time (5 am to 3 pm Pacific time): 1-888-281-5582. Even after hours, there is always a CuraScript representative on call to help you.

Be sure to ask the CuraScript Zavesca Team whether you are eligible for Zavesca Financial Support.

If you'd like to contact Actelion Pharmaceuticals US, Inc., call 1-866-ACTELION (1-866-228-3546).

Zavesca financial support*

  • A financial assistance program available to eligible people taking Zavesca
  • Co-pay and out-of-pocket expenses may be covered
  • The level of assistance may vary depending on whether or not you have insurance

Click image to enlarge.

The National Gaucher Foundation can also help you learn more

National Gaucher Foundation
www.gaucherdisease.org
1-800-504-3189

*This offer is not valid for prescriptions reimbursed or paid under Medicare, Medicaid, or any similar federal or state healthcare program, including any state medical or pharmaceutical assistance programs. Offer not valid in Massachusetts or where prohibited by law.

Read more about Zavesca Cares

What is ZAVESCA?

ZAVESCA is a prescription medicine taken by mouth for adults with mild to moderate type 1 Gaucher disease. ZAVESCA is used only in people who cannot be treated with enzyme replacement therapy.

Important Safety Information for Zavesca:

In clinical studies, the most common adverse events due to Zavesca included weight loss, diarrhea, and trembling in the hand (tremor). Other common adverse reactions were excess gas (flatulence), abdominal pain, and headache. The most common serious adverse reaction was tingling or numbness in the hands or feet with or without pain (peripheral neuropathy). Patients should undergo neurological examination at the start of treatment and every 6 months thereafter; Zavesca should be reassessed in patients who develop symptoms of peripheral neuropathy. Zavesca may cause fetal harm if administered to a pregnant woman. Men should maintain reliable contraceptive methods and not plan to father a child while taking Zavesca and for 3 months after discontinuing treatment.

Please see full Prescribing Information.